{"title":"Low Protein Brown Rice for Preventing Progression of CKD and DKD to End Stage Renal Failure","authors":"Shaw Watanabe","doi":"10.17140/droj-4-e012","DOIUrl":"https://doi.org/10.17140/droj-4-e012","url":null,"abstract":"Editorial | Volume 4 | Number 1| e5 Copyright 2018 by Watanabe S. This is an open-access article distributed under Creative Commons Attribution 4.0 International License (CC BY 4.0), which allows to copy, redistribute, remix, transform, and reproduce in any medium or format, even commercially, provided the original work is properly cited. cc C kidney disease (CKD) is pervasive into aging society, affecting permanent implications on patients’ life. Approximately 10% of the global population has CKD, and millions die each year. The prevalence of CKD was high in Latin America, Europe, East Asia and the Middle East, where approximately 12% of the population has CKD.1 Diabetic kidney disease (DKD) or diabetic nephropathy (DN) is a part of CKD when the patients have diabetes.2 Both CKD and DKD may progressively fall from a normal estimated glomerular filtration rate (eGFR >90 ml/min/1.73 m2) to less than 15, at which point the patient becomes end-stage kidney disease (ESKD). The status of DKD could be estimated by measuring the amount of urinary protein and the serum creatinine, which can be used to calculate the eGFR.","PeriodicalId":385648,"journal":{"name":"Diabetes Research - Open Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115612273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Subhashini Chandrasekaran, B. Szirth, Kim Duong, J. Stroud, H. Cope, Peter Khouri, C. Khouri, K. Soules, California Usa Optovue
{"title":"Ocular Health Screening in a Type 1 Diabetes Mellitus Population","authors":"Subhashini Chandrasekaran, B. Szirth, Kim Duong, J. Stroud, H. Cope, Peter Khouri, C. Khouri, K. Soules, California Usa Optovue","doi":"10.17140/DROJ-4-138","DOIUrl":"https://doi.org/10.17140/DROJ-4-138","url":null,"abstract":"Clinical Study | Volume 4 | Number 1| 12 Copyright 2018 by Szirth BC, et al. This is an open-access article distributed under Creative Commons Attribution 4.0 International License (CC BY 4.0), which allows to copy, redistribute, remix, transform, and reproduce in any medium or format, even commercially, provided the original work is properly cited. cc ABSTRACT Background: Type 1 Diabetes Mellitus is among the most common conditions worldwide, affecting nearly 95 million children worldwide. One of the detrimental effects of this condition can be vision loss. Comprehensive annual ocular screenings can have an important role in early detection and management of vision-threatening complications. Over 2,200 family members and children with diabetes type 1 (www.childrenwithdiabetes.com) from Australia, Asia, Canada, Europe, Latin America and the United States of America attended an annual meeting where participants wishing to undergo a full ocular wellness screening had to pre-register for this weeklong activity.","PeriodicalId":385648,"journal":{"name":"Diabetes Research - Open Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134106933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"More Significant Life for Diabetic Patients in the Perspectives of Anti-Aging","authors":"H. Bando","doi":"10.17140/DROJ-4-137","DOIUrl":"https://doi.org/10.17140/DROJ-4-137","url":null,"abstract":"Opinion | Volume 4 | Number 1| 9 Copyright 2018 by Bando H. This is an open-access article distributed under Creative Commons Attribution 4.0 International License (CC BY 4.0), which allows to copy, redistribute, remix, transform, and reproduce in any medium or format, even commercially, provided the original work is properly cited. cc For the patients with diabetes, basal daily lifestyle would be considered in the light of meal, exercise, rest, alcohol intake, smoking and oral health. These six factors are from the concept as a basic direction of “Health Japan 21” for comprehensive implementation of national health promotion.1 Satisfactory control of lifestyle can lead to protection and treatment of diabetes and successful anti-aging. From this implication, to check up physical and mental condition would be important and helpful in clinical practice.","PeriodicalId":385648,"journal":{"name":"Diabetes Research - Open Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121789344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Abe, M. Nakanishi, Osami Watanabe, H. Kawano, H. Bando
{"title":"Attenuated Efficacy of Dulaglutide in Elder Type 2 Diabetes Mellitus (T2DM) Cases","authors":"T. Abe, M. Nakanishi, Osami Watanabe, H. Kawano, H. Bando","doi":"10.17140/DROJ-4-136","DOIUrl":"https://doi.org/10.17140/DROJ-4-136","url":null,"abstract":"Acute increase of type 2 diabetes mellitus (T2DM) is a serious medical problem. Recently, an agent known as Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was developed for T2DM which has remarkable efficacy and safety profile. In this article, we reported 2 T2DM cases with dulaglutide treatment, showing interesting clinical course. Case 1 is an 88-year-old man with hypertension, arteriosclerosis and mild cognitive impairment (MCI) without difficulties of Quality of Life (QOL)/Activities in Daily living (ADL) in daily life. He has been rather stable on liraglutide with HbA1c 7.2%. After switching from liraglutide to dulaglutide, HbA1c decreased to 6.7% in 2 months, but later increased to 11.3% in 3 months. C-peptide index (CPI) decreased from 2.5 to 0.8. Case 2 is an 83-year-old man and was treated by degludec with CPI 1.35. After switching to dulaglutide, HbA1c decreased to 7.6% in 2 months, but later increased to 10.3% in 2 months. These two cases revealed similar clinical course. Some possibilities might be speculated, including antibody production, differences of GLP-1 RAs from man-origin or lizard-origin, changes in body weight, a possible complication of renal, hepatic inflammatory influences and the subacute decreased ability of insulin secretion in the β cells. The current report would be useful for treatment of GLP-1 RAs in the future.","PeriodicalId":385648,"journal":{"name":"Diabetes Research - Open Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131378076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
